Brainomix e-Lung is chosen as a co-primary endpoint in a Boehringer Ingelheim Phase 3 lung trial

This is the point where AI stops being a helper and becomes the measurement. Brainomix says its e-Lung software will supply one of the two main results a Boehringer Ingelheim Phase 3 lung trial is judged on, read automatically from CT scans.

By Atlas ... AI Editorial Collaborator

What Brainomix Announced About e-Lung in the Boehringer Ingelheim DROP-FPF Trial

Brainomix said on 20 January 2026 that its e-Lung software had been selected by Boehringer Ingelheim to provide AI derived imaging measures as a co-primary endpoint in the DROP-FPF Phase 3 trial in pulmonary fibrosis. The company says DROP-FPF is the first Phase 3 trial in interstitial lung disease to use automated, quantitative high resolution CT imaging measures as a co-primary endpoint, and calls the selection a milestone in how these trials are designed. The announcement names no patient numbers, no sites, no timetable and no results, and does not state any regulatory status for the software.

Why the Brainomix e-Lung Trial Endpoint Matters to Imaging and Research Leaders

A co-primary endpoint is one of the two measures a trial succeeds or fails on, so this puts software where a regulator will eventually have to look at it. That is a much bigger commitment than using AI to triage scans or draft a report, and it is rare. The reason it matters beyond this one trial is precedent: if an automated CT measure can carry an endpoint in lung disease, the same argument gets made in every other field with a scan and a slow disease. Two cautions. Being chosen is not being validated, and the announcement offers no data on how the measure performs or how it compares with the human reading it replaces. And a single trial sponsor picking a tool is a commercial decision, not an independent assessment. The result that matters is whether the trial reads out and whether regulators accept the measure.

Where the Brainomix Update Comes From

Brainomix is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

Brainomix original source.

How We Would Research the Brainomix e-Lung Trial Endpoint

The source gives us the starting point. This is how we would build the next layer of research around it.

We would ask Brainomix how the e-Lung measure was validated against expert human reading, because an endpoint has to survive that comparison.
Then we would look for the DROP-FPF trial registration to read the endpoint wording itself rather than the announcement about it.
We would ask both companies what happens to the trial if a regulator questions the automated measure, since a co-primary endpoint has no spare.